Drugs / Zika Virus Purified Inactivated Vaccine
Zika Virus Purified Inactivated Vaccine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03008122 | Mar 2017 → Aug 2021 | Zika virus infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT02937233 | Dec 2016 → Jun 2018 | Zika virus infectious disease | Kathryn Stephenson | Completed | No outcome recorded |
| Phase 1 | NCT02963909 | Nov 2016 → Oct 2018 | Zika virus infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zika Virus Purified Inactivated Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02963909 ↗ |
| Known as | Zika purified inactivated virus | “A Zika purified inactivated virus (ZPIV) vaccine candidate has been shown to protect animals against Zika virus challenge and to be well tolerated and immunogenic in humans up...” PMID 32618279 ↗ May 2020 |
| Known as | ZPIV | “A Zika purified inactivated virus (ZPIV) vaccine candidate has been shown to protect animals against Zika virus challenge and to be well tolerated and immunogenic in humans up...” PMID 32618279 ↗ May 20202“Zika Virus Purified Inactivated Vaccine (ZPIV)” NCT03008122 ↗ “purified inactivated Zika vaccine (ZPIV)” PMID 37390836 ↗ Jun 2023 |
| Modality | Vaccine | “a purified formalin-inactivated Zika virus vaccine (ZPIV) candidate” PMID 29217375 ↗ Dec 2017 |
| Route | Intramuscular | “receive an intramuscular injection of 5 μg ZPIV or saline placebo” PMID 32618279 ↗ May 2020 |